核糖体结合蛋白在甲状腺癌中的表达及其与临床病理特征的关系

目的:探讨核糖体结合蛋白1(RRBP1)在甲状腺癌组织中的表达及其表达与临床病理特征的关系。方法:采用免疫组织化学方法检测RRBP1在86例甲状腺癌和15例癌旁正常组织中的表达,并分析其表达与临床病理特征的关系。结果:RRBP1在甲状腺癌及癌旁正常组织中表达的阳性率分别为77.9%和20.0%,差异有统计学意义(P<0.01)。甲状腺癌组织中RRBP1表达在肿瘤直径≥2 cm、TNM分期Ⅲ~Ⅳ期及淋巴结转移患者中的表达均明显高于肿瘤直径< 2 cm、TNM分期Ⅰ~Ⅱ期及无淋巴结转移患者(P<0.05),而在患者不同年龄、性别、吸烟史及肿瘤好发部位间的表达阳性率差异均无统计学意义(P>0.05)。结论:RRBP1可作为甲状腺癌发生相关的新型分子标志物,其表达与患者的临床病理特征相关。

Expression of ribosome binding protein 1 in thyroid cancer and its relationship with clinicopathological characteristics

Objective:To explore the expression of ribosome binding protein 1(RRBP1) in thyroid cancer and its relationship with clinicopathological characteristics. Methods:The expressions of RRBP1 in 86 thyroid cancer specimens and 15 adjacent normal tissue specimens were detected using immunohistochemical method, and the relationship between the expression of RRBP1 and clinicopathological characteristics of thyroid cancer was analyzed. Results:The positive rates of RRBP1 expression in thyroid cancer and normal tissue were 77. 9% and 20. 0%,respectively,and the difference of which was statistically significant(P<0. 01). The positive rates of RRBP1 in thyroid cancer patients with tumor size≥2 cm,stage Ⅲ-Ⅳ and lymph node metastasis were significantly higher than that in the patients with tumor size<2 cm,satgeⅠ-Ⅱand non-lymph node metastasis(P<0. 05). The differences of the positive rate of RRBP1 expression in different ages,sex,smoking history and tumor location were not statistically significant(P >0. 05). Conclusions:RRBP1 can be used as a novel molecular marker in the occurrence of thyroid cancer,and its expression is closely related to the clinicopathological characteristics.